COMP <GO>
CNMD vs ABBV // EV/EBITDA & P/E VALUATION
CONMED Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CNMD 3
— ABBV 9
▲ EV/EBITDA & P/E VALUATION LEADER: CNMD
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
valuation
11.4x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 70.20% | -15.60 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 29.00% | -21.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 11.4x | 33.3x | -21.90 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | 3.47% | +7.60 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | 24.60% | -17.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 6.90% | -3.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 8.60% | -3.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.82% | 2.27% | -0.45 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 5.33 | -3.42 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 65.1 | -24.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 113.1x | -86.20 | CNMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $513.86B | -$512.50B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | ABBV REV | CNMD GROSS % | ABBV GROSS % | CNMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $61.16B | 54.6% | 70.2% | $150.9M | $17.82B |
| FY 2024 | $1.31B | $56.33B | 56.1% | 70.0% | $153.9M | $17.83B |
| FY 2023 | $1.24B | $54.32B | — | — | $125.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
ABBV // BETA 1.15